Past Issues – Page 6 – The Cancer Letter

Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 34 - Sep. 13, 2019

TCL45-34 (243 downloads)

Guest Editorial
Why CAR-T policymaking is broken, and why we need to fix it
The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.
The 2019 Lasker Awards go to: Max D. Cooper, Jacques Miller, Michael Shepard, Dennis J. Slamon, Axel Ullrich, and Gavi, the Vaccine Alliance
The Lasker Foundation has named the winners of the 2019 Lasker Awards: Max D. Cooper, Jacques Miller, Michael Shepard, Dennis J. Slamon, Axel Ullrich, and Gavi, the Vaccine Alliance.
In Brief
- DeAngelis named MSK physician-in-chief, chief medical officer
- Bondy named chair of Stanford Epidemiology and Population Health Department
- Farrar named CEO at Ohio State James Cancer Hospital and Solove Research Institute
- Yang appointed director of Division of Hematology at Ohio State
- Patierno receives AACR Distinguished Lectureship on the Science of Cancer Health Disparities
- Samuel Waxman Cancer Research Foundation awards $1.4 million in grants
- Purdue and Frederick National Laboratory form partnership focused on big data approach to cancer
- Bauml, Lai, and Lisberg receive LUNGevity 2019 Career Development Awards
- UMN researchers awarded grant in metastatic breast cancer
- Fortin departs Winship for UCLA Health
Conversation with The Cancer Letter
Michigan’s Philip Stella receives NCORP 2019 Harry Hynes Award
Philip J. Stella, the principal investigator of the Michigan Cancer Research Consortium NCI Community Oncology Research Program site in Ann Arbor, won the 2019 Harry Hynes Award.
Clinical Roundup
- IMFINZI is first immunotherapy to show OS benefit, improved, durable responses in extensive-stage SCLC
- Pooled five-year survival results show OS advantage for Opdivo in advanced NSCLC
- LOXO-292 shows 68% ORR, sustained durability in heavily pretreated RET fusion-positive NSCLC
- ASTRO guideline clarifies role of radiation therapy in pancreatic cancer treatment
- Study shows higher risk of death in patients with CV conditions who receive novel oral prostate cancer therapies
Drugs & Targets
- Adaptimmune receives Orphan Drug Designation for SPEAR T-cells targeting MAGE4-A in soft tissue sarcoma
- BioXcel receives Orphan Drug Designation for BXCL701 in AML

Issue 33 - Sep. 6, 2019

TCL45-33 (299 downloads)

MD Anderson’s Stephen Hahn emerges as candidate for FDA commissioner’s job
The game of musical chairs involving topmost jobs in oncology has gathered speed and expanded beyond FDA and NCI, pulling in premier positions at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
NCI Director’s Report
Lowy: NCI needs 15% budget increase to reach FY2021 goal of 15th percentile for paylines
NCI is requesting an increase of $989 million to its FY2021 budget over FY2019 appropriated levels to boost the institute’s payline, which has dropped to the 8th percentile in FY19—lower than 2013 sequestration levels—and which has been steadily dropping despite increased overall funding in recent years.
Guest Editorial
Skyfall falls to earth
Why Americans and Russians should be worried
It’s difficult to discern reason, let alone strategy, in the Russian government’s response after the Skyfall missile (called the 9M730 Burevestnik by the Russian military and SSC-X-9 Skyfall by NATO) exploded during a test Aug. 8.
The accident occurred in the vicinity of the town of Severodvinsk. A radioactive cloud dispersed by tropospheric winds is easily and rapidly detected outside Russia—so there was no hiding the accident.
In Brief
- Cance named American Cancer Society chief medical and scientific officer
- Wakelee named president-elect of IASLC
- Van Cutsem, Di Leo, Sessa, Swanton win 2019 ESMO awards
- Tobacco expert Berg joins GWU Cancer Center
- Bradley named executive vice chairman of Winship Department of Radiation Oncology
- Lou named CTO medical director and Holtan named CTO-CGI medical director at Masonic Cancer Center
- WashU researchers awarded $15 million to study genetic drivers of AML
- Bowles, Shafer, Pennisi, and Saqib join Inova
- Blue Cross & Blue Shield of Minnesota and Minnesota Oncology announce five-year collaboration
Funding Opportunities
LLS announces $50 million initiative for pediatric blood cancer research
The Leukemia & Lymphoma Society announced that it has more than doubled its funding of research focused specifically on childhood blood cancers, adding 20 new research grants valued at more than $13.8 million to its research portfolio in 2019.
Clinical Roundup
- Health insurance, ZIP code matters when it comes to benefiting from cancer trials
- Combination therapy found effective for multiple myeloma patients
- GSK announces positive results from the DREAMM-2 study for multiple myeloma
Drugs & Targets
- FDA approves entrectinib, third tissue agnostic drug
- Syapse, FDA form research collaboration on the regulatory use of real-world evidence
- Calquence granted Breakthrough Therapy designation for CLL
- European Commission approves Empliciti + pomalidomide and dexamethasone for multiple myeloma
- European Commission approves Imbruvica for expanded use in two indications
- FDA Grants XTANDI application Priority Review for metastatic hormone-sensitive prostate cancer
- DARZALEX approved for frontline multiple myeloma in Japan
- FDA draft guidance encourages inclusion of male patients in breast cancer clinical trials
NCI Trials
NCI Trials for September
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 34 - Aug. 9, 2019

TCL45-34 (600 downloads)

Letter from the Editor
The Summer Issue of The Cancer Letter
You are looking at The Cancer Letter’s summer issue, a collection of stories we have compiled for you as we (and, we hope, you) go off on a brief summer recess.
Guest Editorial
Learning from suramin: A case study of NCI’s much-hyped cancer drug that crashed and burned—35 years ago
Almost 35 years ago, while the nation suffered in the vicious grip of the HIV epidemic, a young man from South Carolina with AIDS named Boyd Helton found his way to the NIH Clinical Center in Bethesda. While there, he was recruited into a clinical research protocol designed to lower the expression of viral proteins in his blood, and, ideally, to increase the numbers of his circulating CD4+ T-cells.
Robert Peter Gale’s series of stories on the HBO drama Chernobyl
Gale was there, in Moscow’s Hospital Number 6, famously taking care of people injured in the nuclear plant disaster. He is also the author of two books that address Chernobyl, other nuclear accidents and radiation in general: “Final Warning” and “Radiation: What It Is, What You Need to Know.”
When Surgical Innovation Kills
Over the past six years, The Cancer Letter has been investigating the hidden hazards in minimally invasive surgery, finding that in some cases, machines and surgical techniques that inadvertently spread cancer cells go into routine use without anyone bothering to ask life and death questions.
Slamming the Door
On Nov. 5, Texas voters will decide on Proposition 6, which would authorize a second installment of $3 billion in General Obligation Bonds for Cancer Prevention and Research Institute of Texas. CPRIT is a unique state-funded initiative that is distributing $300 million a year to cancer research and other cancer causes in Texas.
To the Moon
For the past three years, The Cancer Letter has been covering the U.S. government’s Cancer Moonshot initiative.
Conversation with The Cancer Letter
Indiana University Simon Cancer Center becomes 51st NCI-designated comprehensive cancer center
The Indiana University Melvin and Bren Simon Cancer Center has achieved comprehensive status—becoming the only NCI-designated comprehensive cancer center in Indiana.
Trials and Tribulations
Measures to improve clinical trial enrollment: Marshfield Clinic Cancer Care and research approach
Part II of a two-part series
It is estimated that, each year, as few as 2–3% of cancer patients enter clinical trials. In part I of this series, we discussed four key barriers to participation: physician barriers, protocol barriers, research team barriers, and insurance barriers. In part II, we will look at solutions to these barriers and how to implement them in the clinical setting.

Page 6 of 116« First «...2 3 4 567 8 9 10 11...20 30 40 50 60 70 80 90 100 110...»Last »